Skip to main content
. 2021 Jan 6;11(1):31. doi: 10.3390/jpm11010031

Figure 7.

Figure 7

Both miR-210 and miR-152 are stable in blood. (a) For the breast cancer (BC) group, relative quantification showed that there was increased expression of miR-210 in plasma samples when compared with fragments. (b) The same occurred for miR-152; the relative quantification of this miRNA was higher in plasma samples compared to fragments. (c) There was no significant difference in circulating levels between miRNAs. Significant value in Kruskal–Wallis and Dunn’s post test (±SEM - standard error of the mean; ** p < 0.01; *** p < 0.01).